الفهرس 
Pharmaceutical studies on ocular drug delivery systems for treatment of glaucoma
ContentsOnly 14 pages are availabe for public view
 |  | from | 223 |  |  |
| | | from | 223 | | |
Abstract
Novel sustained release topical drug delivery systems are more preferable than conventional topical dosage forms for ocular administration as they enable dose reduction, patient compliance and avoid the drug loss associated with liquid eye drops. Glaucoma is one of the most serious ocular diseases as it is characterized by increased IOP and optic nerve damage that can lead to blindness, so it must be under controlled treatment to avoid its complications. Brimonidine is Ü2 adrenergic agonist which has a dual mechanism of action in reducing intraocular pressure; (i) it decreases aqueous humor production and (ii) it increases the uvo-scleral outflow by increasing prostaglandins synthesis.Also, it is reported that brimonidine displays neuroprotective action when tested in several animal models of glaucoma. This neuroprotective action is guarding against photoreceptor degeneration and ischemia-induced optic nerve damage. Due to the hydrophilicity and the poor bioavailability of brimonidine tartrate, it should be taken three times daily for a lifetime to prevent blindness. This high dosing frequency hinders patient compliance; therefore formula of a sustained ocular drug delivery system of brimonidine is a major concern for glaucoma patients. The aim of this study is to improve the ocular bioavailability of BRT and to provide the patient with a once daily dose i.e. to sustain brimonidine tartrate IOP lowering effect for 24 hours